Shots:
- Q32 Bio has sold ADX-097, a P-II complement inhibitor, to Akebia Therapeutics
- As per the deal, Akebia will acquire ADX-097 from Q32 Bio for ~$592M, incl. $12M in upfront & near-term milestones ($7M at signing, $3M after 6mos., $2M payable upon the earlier of a milestone or end-2026), plus development, regulatory & commercial milestones & tiered royalties, ranging from low single-digit to mid-teen %
- Q32 Bio retains rights to its tissue-targeted complement inhibitor platform, incl. ADX-096 & early assets, & is pursuing strategic options for these programs, while advancing bempikibart for Alopecia Areata, with Part B topline data from P-IIa (SIGNAL-AA) trial expected in mid-2026
Ref: Q32 Bio | Image: Akebia Therapeutics and Q32 Bio | Press Release
Related News: Akebia’s Vafseo (Vadadustat) Tablets Gain the US FDA’s Approval to Treat Anemia Due to CKD
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
